ArticleJournal of molecular medicine (Berlin, Germany)2025
NO/iNOS axis impact on glioma stem cells and temozolomide resistance.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Glioblastoma (GB), the most aggressive brain tumor invariably recurs despite conventional treatment (surgery, chemotherapy with temozolomide (TMZ), radiotherapy), a phenomenon linked to glioma stem cells (GSC). This study demonstrates that inducible nitric oxide synthase (iNOS)-derived nitric oxide (NO) sustains the GSC niche and contributes to TMZ resistance. In silico analysis of 695 glioma samples from The Cancer Genome Atlas showed that higher iNOS expression correlates with poor patient survival. In vitro, GSC-enriched cultures (spheres) from GB cell lines (LN229, U87, U251, GL26) exhibited elevated pluripotency (Nestin gene expression), iNOS expression and NO levels threefold higher than more differentiated cell cultures (2D and 3D-spheroids). The iNOS inhibitor S-methylisothiourea (SMT) effectively reduced NO production. Sequential treatment with TMZ followed by TMZ + SMT more effectively reduced viability in 2D and 3D-spheroids growth compared to TMZ alone. In GSC enriched spheres, SMT decreased GSC frequency and growth, and combined TMZ + SMT showed enhanced reduction. Primary human glioma cultures (n = 11) expressed iNOS and their GSC spheres formation efficiency was reduced by SMT. These findings suggest that iNOS/NO axis is critical for GSC maintenance and TMZ resistance. Sequential TMZ followed by iNOS inhibition shows promise as a therapeutic strategy against GB recurrence by targeting GSCs. KEY MESSAGES: Elevated iNOS expression correlates with poor glioma prognosis markers. Temozolomide acts on more differentiated glioma cells and enriches stem cells. iNOS inhibition reduces the stem cell niche, enhancing TMZ sensitization.
Indexed as
Identifiers
41452357What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.